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Aminoacyl-tRNA synthetases (ARSs) are ubiquitous, ancient enzymes that charge amino acids to cognate tRNA molecules, the essential
first step of protein translation. Here, we describe 32 individuals from 21 families, presenting with microcephaly, neurodevelopmental
delay, seizures, peripheral neuropathy, and ataxia, with de novo heterozygous and bi-allelic mutations in asparaginyl-tRNA synthetase
(NARS1). We demonstrate a reduction in NARS1 mRNA expression as well as in NARS1 enzyme levels and activity in both individual
fibroblasts and induced neural progenitor cells (iNPCs). Molecular modeling of the recessive c.1633C>T (p.Arg545Cys) variant shows
weaker spatial positioning and tRNA selectivity. We conclude that de novo and bi-allelic mutations in NARS1 are a significant cause of
neurodevelopmental disease, where themechanism for de novo variants could be toxic gain-of-function and for recessive variants, partial
loss-of-function.Introduction
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mitochondrial enzymes. Despite the essential canonical
function and ubiquitous expression of ARS enzymes, mu-
tations in these genes have been implicated in a variety
of human diseases with both recessive and dominant in-
heritance patterns.2,4–6 These mutations result in neuro-
logical disorders, ranging from mild late-onset peripheral
neuropathy to severe multi-systemic neurodevelopmental
disorders4,5,7–9 (Table S1).
Mutations in cytoplasmic ARS-encoding genes cause pe-
ripheral nervous system degeneration resulting in Charcot-
Marie-Tooth neuropathies (GARS1 and AARS1 [MIM:
601065]) and brain stem and spinal cord hypomyelination
(DARS1 [MIM: 603084]). ARSs, and ARSs interacting genes,
including DARS1, RARS1 (MIM: 107820), AIMP1 (MIM:
603605), and AARS1, have been implicated in neurodeve-
lopmental disorders and epilepsies. Furthermore, mito-
chondrial ARS2 mutations are often associated with leu-
koencephalopathy (AARS2 [MIM: 615889] and DARS2
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neurodevelopmental phenotypes.10–14 Modes of inheri-
tance can be dominant or recessive; in cases such as
AARS1, YARS1 (MIM: 603623), MARS1 (MIM: 156560),
HARS1 (MIM: 142810), and GARS1, both patterns can
occur.6
The loss of function associated withmutations in ARSs is
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to a loss of primary aminoacylation.15–17 Overall, the phys-
iological functions of ARS genes and previously identified
disease associations indicate an essential biological role
for these proteins, implying that defects in all ARSs incur
disease.6
Asparaginyl-tRNAAsn is generated by asparaginyl-tRNA
synthetase (NARS1 (MIM: 108410; RefSeq accession
number NM_004539.4] in a reaction involving two
steps. NARS1 first catalyzes the ATP-dependent activa-
tion of asparagine (Asn) into AsnAMP with the release
of pyrophosphate, and then transfers the activated Asn
onto tRNAAsn with the release of AMP (Figure 1A).
Here, we report the clinical phenotypes associated with
de novo dominant and bi-allelic, autosomal recessive mu-
tations in NARS1 in 32 affected individuals from 21
families. We provide genetic proof for these mutations
and analyze their impact through the use of individual
cell lines, neural progenitor cells, and molecular
modeling.Subjects and Methods
Study Participants
Individuals were recruited via an international collaborative
network of research and diagnostic sequencing laboratories. Sam-
ples and clinical information were obtained, with informed con-
sent, from each institution using local institutional review board
(IRB) ethics for functional analysis of human DNA and biomate-
rial. Clinical data collection involved a detailed review of medical
records, photographs, videos, and phone interviews, as well as a
clinical re-evaluation by a neurologist. Tables S2–S4 summarize
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Figure 1. AsnRS1 Protein Structure and Function
(A) AA asparagine (Asn) is ligated to tRNAAsn and catalyzed by AsnRS1 and ATP to produce Asn-tRNA (Asn), AMP, and pyrophosphate.
(B) NARS1 mutations and their predicted functional effect.
(C) Schematic representation of human ARS1 primary structure. Three main domains are depicted: the unique domain (UNE-N), the
anticodon binding domain (ABD), and the catalytic domain (CAT). The nature and position of themutants are shown above the primary
structure, de novo boxed in red, and the positions of the domains are indicated below, including motif 1 (involved in AsnRS1 dimeriza-
tion) and motifs 2 and 3 (which form the active site).
(D) Bar graph summarizing proportions of various clinical findings affecting individuals with NARS1 mutations.Sequencing
Exome sequencing was carried out using a number of methods in
different centers with different analysis platforms and pipelines
used (see Supplemental Methods, Section 2).Bioinformatic Analysis
cDNA and protein sequence variants are described in accordance
with the recommendations of the Human Genome Variation Soci-
ety using Ensembl ENSG00000134440 and ENST00000256854.10
as the reference sequences. Evolutionary conservation of nucleo-
tides was assessed using PhyloP (46 vertebrate species) and
genomic evolutionary rate profiling (GERP) scores.18 These were
accessed through the University of California—San Francisco
(UCSC) Genome Browser19 using genomic coordinates from
GRCh37/hg19. Grantham scores were used to assess the physico-
chemical nature of the amino acid (AA) substitutions. In silico an-
alyses of sequence variants were performed using the pathoge-The Americnicity prediction tools SIFT, PolyPhen-2, and Mutation Taster
version 2.
Our bioinformatics filtering strategy screened for exonic and
donor/acceptor splicing variants. In accordance with the pedigree
and phenotype, priority was given to rare variants (<0.01% in
public databases, including 1000 Genomes Project; National
Heart, Lung, and Blood Institute [NHLBI] Exome Variant Server;
Complete Genomics 69; and Exome Aggregation Consortium
[ExAC v0.2]) fitting a recessive (homozygous or compound
heterozygous) or a de novo model and/or variants in genes previ-
ously linked to epilepsy, developmental delay, intellectual
disability, and other neurological disorders. Upon whole-exome
sequencing (WES) analysis of the index family (F9), the NARS1
variant c.1633C>T (p.Arg545Cys) was picked up according to its
frequency and prediction tool scores (SIFT—damaging [score ¼
1], PolyPhen—damaging [score ¼ 1], GERP—5.5, Mutation
Taster—0.999992). All the candidate variants were further verified
through the use of Sanger sequencing.an Journal of Human Genetics 107, 311–324, August 6, 2020 313
Generation of the nrs1 Vector
The pJR1-41XU-nrs1 expression vector was used to express Schizo-
Saccharomyces pombe nrs1 by amplifying the coding sequence of
nrs1 from S. pombe DNA with the Nrs1-PJR-F and Nrs1-PJR-R
primers (all primers are provided in Table S5) through the use of
Phusion HF polymerase from New England Biolabs (NEB). The
PCR product was cloned into XhoI digested pJR1-41XU20 through
the use of CloneEZ from Genscript. Plasmids were sequenced to
confirm the correct insertion of the fragment.
Deletion of nrs1 Gene in S. pombe Cells
JB775 (h- ade6-M216 ura4-D18 leu1-32) cells were synchronized,
made competent, and transformed as previously described.21 Cells
were transformed using the plasmid containing the nrs1 gene,
pJR1-41XU-nrs1, and transformants were selected according to
growth in Edinburgh minimal medium (EMM)þ adeþ leu, gener-
ating the strain MR397. The nrs1 gene was deleted in MR397 cells
through the use of the standardmethod via homologous recombi-
nation with the NatMx6 cassette22,23 using the primers Nrs1DelFw
and Nrs1DelRv (Table S5). Transformants were selected in EMM þ
Nat with no thiamine to promote the expression of the nrs1 gene
from the plasmid. Deletions were checked via PCR using primers
Nrs1ck-L and kanR and Nrs1ck-R and kanF (Table S5). The strain
generated was named MR409. MR409 cells were synchronized,
made competent, and transformed as previously described.21
The plasmids of the pJR-41XL series contained either the empty
vector, wild-type NARS1, or the NARS1 variants described. Trans-
formants were selected in EMM þ ade strains.
Cell Culture
Fibroblasts of affected individuals carrying the homozygous
c.50C>T (p.Thr17Met), c.32G>C (p.Arg11Pro), and c.1633C>T
(p.Arg545Cys) and compound heterozygous c.1067A>C
(p.Asp356Ala) and c.203dupA (p.Met69Aspfs*4), as well as of cor-
responding controls, were grown in high-glucose Dulbecco’s
modified Eagle’s medium (Sigma) supplemented with 10% fetal
bovine serum and 1% penicillin and streptomycin.
Semiquantitative RT-PCR for Individual Lymphoblasts
Using TRIzol (Zymo research), as per manufacturer’s instructions,
total RNAwas extracted from immortalized lymphoblasts available
from P2 and parents. The concentration and purity of RNA was
determined spectrophotometrically. 1 mg of RNA was reverse tran-
scribed to first strand cDNA through the use of random primers
and Moloney murine leukemia virus reverse transcriptase (Prom-
ega). GoTaqGreenMaster Mix (Promega) was used and PCR reac-
tions were performed with the following protocol: 95C—2 min
(95C—30 s, 60C—30 s, 73C—1 min) for 35 cycles, 73C—
5min,and4Chold.Twoexponential curves representing theprod-
uct formationwere determined for both primer pairs. Cycles 28 and
29 were chosen for NARS1 and GAPDH, respectively,we so that
amplification rates were in the linear range for semiquantitative
comparisons. Reactions were repeated in triplicate.
Western Blotting
For western blotting analysis, protein lysates were obtained from
cultured fibroblasts and total protein concentration was measured
bymeans of a Bradford assay. Aliquots of total protein (15 mg) were
loaded on 4%–12% sodium dodecyl sulfate (SDS)-polyacrylamide
gels (NuPAGE 4%–12% Bis-Tris Protein Gels, ThermoFisher Scien-
tific), transferred to polyvinylidene fluoride membranes, and314 The American Journal of Human Genetics 107, 311–324, Augustblocked and incubated overnight with a polyclonal antibody
recognizing AsnRS1 (anti-rabbit 1:1000; Proteintech). Secondary
antibody was added for 1 h, and signal was detected using
enhanced chemiluminescence (ECL) reagents (Amersham Biosci-
ences). Anti-beta-actin antibody (Sigma Aldrich, A3853; 1 in
5,000) was used as a loading control. Blots were repeated in tripli-
cate and statistics were performed using Prism 6. Data are pre-
sented as mean 5 standard error of the mean (SEM). The signifi-
cance between the variables was shown based on the p value
obtained (ns indicates p > 0.05, *p < 0.05, **p < 0.005, ***p <
0.0005, ****p < 0.00005).
Blue Native Polyacrylamide Gel Electrophoresis (BN-
PAGE)
Fibroblast pelletswere lysed using 10mMTris (pH8), 150mMNaCl,
0.1% NP40 with physical agitation for 30 min, centrifuged at
8,000xg to remove debris. The supernatant was removed, and total
protein was quantified with the Bradford assay. Protein concentra-
tions were equalized and prepared to 20ml at 1mg/ml using Native-
PAGE sample buffer (Thermo) and 1ul of NuPAGE 5% G-250 Sam-
ple Additive (Thermo), and then loaded to a NativePAGE 3%–
12% Bis-Tris Protein Gel (Thermo). Proteins were transferred to
polyvinylidene fluoride (PVDF) membrane through the use of
an iBlot2 PVDF Mini transfer stack (ThermoFisher Scientific)
and probed with anti-NARS1 monoclonal antibody (Abcam
ab129162, 1:5000) and glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH; Santa Cruz). Blots were repeated in triplicate, and
differences were analyzed using Welch-corrected t test.
Induced Neuronal Progenitor Cell (iNPC) Conversion
Based on the protocol published by Meyer et al.,24 iNPCs were
generated from primary fibroblasts by transduction with Oct4-,
Klf4, and c-Myc-Sendai virus, followed by culturing in neuronal
progenitor cell (NPC) induction media (1:1 DMEM/F-12: Neuro-
basal, 23 N2, 23 B27, 1% GlutaMAX, 10ng/mL hLIF, 3mM
CHIR99021, and 2 mM SB431542). Neuroepithelial colonies were
formed after 3–4 weeks of culturing. These were then isolated
and expanded before we extracted total RNA from individual fibro-
blasts, age and sex matched healthy control fibroblasts, and iNPCs
cells using the mirVana miRNA Isolation Kit (Ambion) for gene
expression analysis by qPCR to confirm iNPC lineage and RNAseq
in control and individual iNPCs in order to identify differentially
expressed genes.
qPCR
Cell pellets from individualfibroblasts and iNPCswere lysedusinga
Trizol reagent. Following the addition of chloroform, the aqueous
phase was transferred to RNeasy spin column (QIAGEN) for RNA
isolation and resuspension. cDNA was generated using the reverse
transcriptase kit (Applied Biosystems) and qPCR (Applied Bio-
systems 7900HT) was performed in triplicates using SYBR Green
PCR Master Mix (Invitrogen, 4309155). Samples were normalized
to expression of GAPDH and b-actin and repeated in triplicate.
RNaseq
Libraries were prepared using Illumina TruSeq Stranded Total RNA
with Ribo-Zero Human kit and were sequenced on an Illumina Hi-
Seq 2500 using a paired-end protocol. Quality of sequencing reads
were ensured using FastQC. Reads were aligned using STAR aligner,
and variants were called using the two-pass protocol outlined in
the GATK documentation (see Web Resources). The numbers of6, 2020
Figure 2. Pedigrees of the 21 Families and 32 Affected Individuals Identified in This Study with de novo and Bi-allelic Mutations in
NARS1
Filled symbols represent affected individuals and double bars represent consanguinity in the family. /, þ/, and þ/þ represent wild-
type, heterozygous, and homozygous variants, respectively.reads were counted using HTSeq-count.25 Differentially expressed
genes were identified using the DESeq2 Bioconductor package.26
Differentially expressed genes with a false discovery rate of %0.1
and a log2 (fold change) R1 were considered significant. Gene
set enrichment analysis was performed using the CPDB web tool.NARS1 Enzyme Assay
Aminoacylation was assessed by measuring NARS1 activity in
cultured fibroblasts and lymphoblasts. Cell lysates (cytosolic frac-
tion) were incubated in triplicate at 37C for 10 min in a reaction
buffer containing 50mmol/L Tris buffer pH 7.5; 12mmol/L MgCl2;
25mmol/L KCl; 1 mg/mL bovine serum albumin; 0.5mmol/L sper-
mine; 1mmol/LATP;0.2mmol/Lyeast total tRNA; 1mmol/Ldithio-
threitol; and 0.3mmol/L [15N2]-asparagine, [
13C4,
15N]-threonine,
[D2]-glycine, [
15N2]-arginine, and [D4]-lysine. The reaction was
terminated using trichloroacetic acid. Ammonia was then added
to release the labeled AAs from the tRNAs. [13C2,
15N]-glycine and
[13C6]-arginine were added as internal standards, and the labeled
AAswere quantified via LC-MS/MS. Intra-assay variation was deter-
mined as <15% of TARS1, GARS1, RARS1 KARS1 activity which
were simultaneously detected as control enzymes. AsnRS1 activities
weremeasuredblind, and testingwas repeated in triplicate.Data are
presented as mean5 SEM. The statistical significance of the differ-
ence of AsnRS1 activity between controls and affected individuals
and/or carriers was determined using a Student’s t test with a 95%
confidence interval through the use of SPSS 26.Molecular Modeling Analysis
The crystal structure of Brugia malayi AsnRS1 with a 65% identity
to humanAsnRS1, stored under the 2XGTcode in the Protein Data
Bank, was used for the molecular modeling analysis. The homol-
ogy model of the dimeric human AsnRS1 overlapped with the
S. cerevisiae DARS-tRNAAsp ligase, co-crystallized with tRNAmole-The Americcule PDB 4WJ4, thus having a similar domain organization and
sharing 27.5% of sequence identity with human AsnRS1. The pro-
tein was visualized with the University of California–San Francisco
Chimera software.27Results
Genetic Analysis
We identified 21 families (F1–F21) and 32 affected individ-
uals (P1–P32) with mutations in NARS1 (Figure 1B shows
NARS1 variant schematic and Figure 2 illustrates pedi-
grees). Eight families had de novo heterozygous variants;
six had c.1600C>T (p.Arg534*) (F1–F6, P1–P6); one had
c.1525G>A (p.Gly509Ser) (F7, P7); and one had
c.965G>T (p.Arg322Leu) (F8, P8). These variants were
not present in our 652 normal brain series or in the
gnomAD database.
Bi-allelic variants were found in thirteen families. Seven
have homozygous c.1633C>T (p.Arg545Cys) variants (F9–
F15, P9–P23); one has homozygous c.50C>T (p.Thr17Met)
(F17, P26); and one has two siblings with homozygous
c.32G>C (p.Arg11Pro) (F16, P24 and 25). For compound
variants, one family has two siblings with compound het-
erozygous c.1067A>C (p.Asp356Ala) and c.203dupA
(p.Met69Aspfs*4) (F19, P29 and P30). Two siblings had
compound heterozygous c.1049T>C (p.Leu350Pro)
and c.1264G>A (p.Ala422Thr) variants (F18, P27 and
P28). There was one case with the compound hetero-
zygous variants c.268C>T (p.Arg90*) and c.394G>T
(p.Gly132Cys) (F20, P31) and a final individual with
compound heterozygous c.1376C>T (p.Thr459Ile) andan Journal of Human Genetics 107, 311–324, August 6, 2020 315
c.178A>G (p.Lys60Glu) variants (F21, P32). In gnomAD,
c.1264G>A (p.Ala422Thr) is present in six heterozygote in-
dividuals, whereas c.1633C>T (p.Arg545Cys) and c.50C>T
(p.Thr17Met) were present in five and four heterozygotes,
respectively. The c.100 A>T (p.Met34Leu), c.203dupA
(p.Met69Aspfs*4), and c.1049T>C (p.Leu350Pro) variants
were absent, while c.32G>C (p.Arg11Pro) was present in
one individual. The c.1067A>C (p.Asp356Ala) variant in
family 19 was present in 264 heterozygotes, suggesting
that this variant may modify the phenotype and be path-
ogenic only when in trans with a severe variant such as
c.203dupA (p.Met69Aspfs*4).
Clinical Characteristics
Table 1 summarizes the core clinical features of affected in-
dividuals with NARS1 defects (see Tables S2–S4 for addi-
tional details). All individuals had global developmental
delay (GDD) and intellectual disability, which varied in
severity from moderate to profound. They had marked de-
lays in language development. Motor development was
also severely impaired, and one individual never acquired
autonomous ambulation. Microcephaly was observed in
the majority of cases (90%). These cases predominantly
presented with primarymicrocephaly; however, secondary
microcephaly was also noted. Epilepsy was highly associ-
ated with the phenotype, affecting 23 cases (74.2%),
with six individuals experiencing seizures below the age
of one. The semiology of these attacks varied, with a
mixture of partial, myoclonic, and generalized tonic-clonic
seizures described. An ataxic gait, poor balance, and dysar-
thria were frequently detected on examination; this sug-
gests an additional neurodegenerative process; however,
no structural abnormality of the cerebellum was observed
on imaging. A demyelinating peripheral neuropathy
occurred in eight individuals (25%) who had distal leg
muscle atrophy. Dysmorphic features described included
abnormal hands (e.g., clinodactyly, fetal finger pad, two-
to-three-toe syndactyly, slender fingers) and/or feet (e.g.,
small feet, toe syndactyly, slender feet). Upslanting palpe-
bral fissures was the most common facial dysmorphism re-
ported. A broad forehead, wide mouth, wide-set teeth, and
low-set ears with overfolded helices were also described.
Skeletal abnormalities including scoliosis, pronounced
thoracic kyphosis, and pes-cavus were also noted. Behav-
ioral traits associated with the phenotype included impul-
sivity, stereotypies with repetitive speech and/or hand
movements, and selective feeding rituals.
Genotype-Phenotype Correlations
Family 16, with the homozygous variant c.32G>C
(p.Arg11Pro), had a particularly severe clinical picture
comprised of severe developmental delay, progressive
microcephaly, refractory seizures from infancy, and ar-
rested myelination with pronounced cerebral atrophy on
MRI (see Supplemental Note, Table S3, and Figure 3).
Otherwise, imaging was normal apart from micro-
cephaly. There was no common structural change across316 The American Journal of Human Genetics 107, 311–324, Augustall cases. Individuals with the de novo c.1600C>T
(p.Arg534*) variant showed severe microcephaly. In one
family with this variant (F6), mild atrophy was observed
(see Supplemental Information, Tables S2–S4, and Figure 3).
Individuals homozygous for c.1633C>T (p.Arg545Cys)
demonstrated hypotonia and predominantly distal weak-
ness. Spasticity was observed in individuals with the
c.32G>C (p.Arg11Pro) or de novo variants.
A demyelinating polyneuropathy was documented in
individuals homozygous for the c.1633C>T (p.Arg545Cys)
variant (P9, P10, and P20), and in one case, this was
confirmed with a sural nerve biopsy (F9, P9). It was also
described in individuals with the de novo c.1600C>T
(p.Arg534*) variant (P1, P2, and P5) and in the family
with the compound heterozygous c.1049T>C (p.Leu350-
Pro) and c.1264G>A (p.Ala422Thr) variants (F18, P27
and P28).
Pathogenicity of NARS1 Variants
NARS1 is intolerant to loss of function (missense variants
constraint is Z ¼ 0.87). We identified de novo NARS1muta-
tions in eight families (F1–F8, P1–P8) with similar pheno-
types. A variant at codon 534 recurred in six families (F1–
F6, P1–P6). The two other de novo variants altered codons
322 and 509. The c.1600C>T (p.Arg534*) variant is located
15 AAs from the end of the 548-AA protein, representing a
potential hotspot for pathogenic mutations. Arginine at
codons 534 and 545 IS universally conserved in AsnRS1
from all three major taxonomic groupings, implying a sig-
nificant structural or functional role.
The homozygous c.1633C>T (p.Arg545Cys) variant was
observed in seven families with recessive disease. This
variant affects the same C-terminal catalytic stretch as
does c.1600C>T (p.Arg534*), and therefore it might have
a comparablemechanistic effect to c.1600C>T (p.Arg534*).
The c.1067A>C (p.Asp356Ala) variant was found in trans
with the only recessive truncating allele observed thus
far at c.203dupA (p.Met69Aspfs*4) (P29 and P30). Two
missense variants (c.965G>T [p.Arg322Leu] and c.653T>C,
p.Asn218Ser) were found in P8; however, because
c.965G>T (p.Arg322Leu) occurred de novo, it could not be
determined whether these variants were in cis or in trans.
Moreover, the frequency of c.653T>C (p.Asn218Ser) in the
gnomAD database (78 heterozygotes) suggests it is unlikely
to be associated with a severe phenotype, leaving
c.965G>T (p.Arg322Leu) as the most likely disease-causing
variant. TheArg322 residue is essential for enzymatic activity
and therefore is predicted to cause impaired enzyme activity.
Both the c.50C>T (p.Thr17Met) and c.32G>C (p.Arg11Pro)
variants are in the N-terminal UNE-N appended domain of
AsnRS1, which is specific to eukaryotes, and has recently
been shown to have chemokine activity.28
Functional Characterization
Western Blotting and RT-PCR
Given the potential loss of function in homozygous
NARS1 individuals, we investigated gene expression levels6, 2020
Table 1. Summary of NARS1 Variants and Clinical Features of Affected Individuals
Variant: Nucleotide, Protein
c.1600C>T,
p.Arg534*
c.1525G>A,
p.Gly509Ser
c.965G>T,
p.Arg322Leu
c.1633 >T,
p.Arg545Cys
c.32G>C,
p.Arg11Pro
c.50C>T,
p.Thr17Met
c.1049T>C
c.1264G>A,
p.Leu350Pro
p.Ala422Thr
c.1067A>C
c.203dupA,
p.Asp356Ala
p.Met69Aspfs*4
c.268 C>T
c.394G>T,
p.Arg90*
p.Gly132Cys
c.1376 C>T,
c.178 A>G,
p.Thr459Ile,
p.Lys60Glu
Variant type de novo
heterozygous
de novo
heterozygous
de novo
heterozygous
homozygous homozygous homozygous compound
heterozygous
compound
heterozygous
compound
heterozygous
compound
heterozygous
Inheritance AD de novo AD de novo AD de novo AR AR AR AR AR AR AR
Family 1–6 7 8 9–15 16 17 18 19 20 21
Affected Individual(s) 1–6 7 8 9–23 24–25 26 27–28 29–30 31 32
Ethnicity/country of origin European UK European Pakistan/North
India
Kosovo Libya German Turkey Canada USA
Age at onset birth birth birth childhood childhood birth birth birth birth childhood
Consanguinity no no no yes no yes No no no no
Presentation severe GDD severe GDD severe GDD severe GDD seizures seizures mod GDD mod GDD severe GDD severe GDD
ID yes yes yes yes yes yes yes yes yes yes
Microcephaly yes no NA yes yes yes yes yes yes yes
Dysmorphic yes yes yes yes no NA no no yes no
Seizures
Affected Individuals
yes
1, 2, 4, 5, 6
yes yes yes
9, 14, 15, 18, 19,
21, 22, 23
yes
all individuals
yes yes
27
yes
all individuals
yes yes
Spasticity
Affected Individuals
yes
3, 4, 6
no yes no
hypotonia in 9,
10, 16, 17
yes
24
na no
hypotonia
na no
hypotonia
yes
Neuropathy
Affected Individuals
Yes
1, 2, 5
NA NA yes
9, 10, 20
NA NA yes NA NA NA
Ataxia
Affected Individuals
yes
all individuals
NA Yes yes
9–12, 21
NA NA yes NA yes yes
AD ¼ autosomal dominant, AR ¼ autosomal recessive, GDD ¼ global developmental delay, ID ¼ intellectual disability Mod ¼ moderate, NA ¼ not available.
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Figure 3. Radiological Findings of Individuals in Our Cohort
Set 1: Individual homozygous for c.32G>C (p.Arg11Pro). Upper row images (coronal T2-WI [1A] and axial T1-WI [1B]) at the age of
10 months show severely delayed myelination and fronto-temporal atrophy. Lower row images (axial T2-WI [1C] and axial T1-WI
[1D]) repeated at the age of 18 months show progressive and global brain atrophy with an emerging pattern of severe hypomyelination.
Set 2: An additional homozygous c.32G>C (p.Arg11Pro) individual. Upper row images (axial T2-WI [2A] and axial T1-WI [2B]) at the age
of 8 months showmild fronto-temporal underdevelopment and severely delayed myelination. Lower row images (axial T2-WI [2C] and
axial T1-W1 [2D]) repeated at the age of 2 years shows progressive and global brain atrophy along with severe hypomyelination.
(legend continued on next page)
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Figure 4. Protein Levels of AsnRS1 Are
Reduced in Individual-Derived Cells
(A) RT-PCR of the de novo c.1600C>T
(p.Arg534*) variant in P2 and parents (B) west-
ern blotting and (C) quantification graph of
individuals with NARS1 mutations com-
pared with controls. Ctrl ¼ control, P10 ¼ ho-
mozygous c.1633C>T (p.Arg545Cys), P26 ¼
homozygous c.50C>T (p.Thr17Met), P29 ¼
compound heterozygous (c.1067A>C
(p.Asp356Ala) and c.203dupA (p.Met69Aspfs*
4) (F denotes father of individuals), P24 ¼ ho-
mozygous c.32G>C (p.Arg11Pro).through the use of semiquantitative PCR and protein
levels through western blotting of AsnRS1 from lympho-
blasts and fibroblasts from families harboring the
p.Arg545Cys, p.Thr17Met, p.Asp356Ala, p.Met69Aspfs*4,
and p.Arg11Pro variants. In all instances, both gene
expression and protein levels are reduced (Figure 4A–4E).
iNPCs
iNPC colonies were produced and isolated from fibroblasts
from P26 (c.50C>T), P29 (c.1067A>C), and P30
(c.203dupA). From the isolated colonies, gene expression
was determined by using qPCR to select iNPC populations
which presented decreased expression of fibroblast
markers COL1A1, COL3A1, TWIST2, and DKK3, as well as
increased numbers of NPC markers NES, SOX1, and MSI1,
and the iNPC populationwas expanded to be subsequently
used for RNA sequencing (RNaseq). RNaseq showed
normal NARS1 expression in iNPCs from affected individ-
uals carrying the c.50C>T and c.1067A>C mutations,
and decreased expression of the c.203dupA NARS1 allele
in the P29 cells. Interestingly, iNPCs from affected individ-
uals show increased expression of several other ARSs
(DARS1, GARS1, RARS1, SARS1, TARS1, WARS1, and
YARS1) (Figure 5). This could be explained by the fact
that the NARS1 mutant(s) are inducing the integrated
stress response (ISR), which activated a number of ARS
genes as a result of the loss-of-function homozygous reces-
sive variants. Impaired synthetase functionmay reduce the
amount of charged tRNA available for translation elonga-
tion, with a possible increase in the levels of uncharged
tRNA. Uncharged tRNAs produced as a result of AA depri-
vation have been reported to bind GCN2, leading to the
activation of the ISR.29Analysis of the cellular pathways
(Reactome, Gene Ontology) associated with genes with
significantly altered mRNA levels showed that upregulatedSet 3: Individual homozygous for c.50C>T (p.Thr17Met). Axial fluid-a
show global atrophy involving the cerebral and cerebellar hemisphe
Set 4: MRI images of an individual with the homozygous c.1633C>T
sagittal T1-WI (4C) at the age of 4 years; coronal T1-WI (4D), axial T2
T2-WI (4G), axial FLAIR (4H), and sagittal T2-WI (4I) at the age of 20
the three different ages. This individual had an upper thoracic scoliosi
the sagittal T2-WI of the spine (4J) and frontal projection radiograph
The Americgenes were enriched (adjusted p value< 0.01) for pathways
heavily associated with protein translation and processing
such as endoplasmic reticulum (ER) and Golgi protein pro-
cessing and ribosomal homeostasis. In addition, increased
action of VEGFR1/2 (upregulated by ATF4, which is one of
the key transcription factors in the ISR) was suggested.
Blue-Native Polyacrylamide Gel Electrophoresis (BN-PAGE)
Similar to most other disease-associated ARSs, AsnRS1
functions as a class II homodimer.30 We showed severely
reduced dimer formation in P26 (c.50C>T [p.Thr17Met])
and P29 (c.1067A>C [p.Asn356Ala] and c.203dupA
[p.Met69Aspfs*4])comparedtohealthycontrols (Figure5E).
The unaffected parents carrying one heterozygous muta-
tion each also appeared to show a decreased level of the
AsnRS1 dimer. P10 (c.1633C>T [p.Arg545Cys]) showed an
AsnRS1dimer amount comparable to thathealthy controls.
The decreased AsnRS1 dimer formation observed in fibro-
blasts from P26 and P29 shown by BN-PAGE accounts for
the apparent deficit in aminoacylation capacity, despite
showing no consistent decrease in the levels of AsnRS1
monomers. This idea is further supported by the molecular
model simulation (Figure 6) that predicts an unstable dimer
for the p.Asn356Ala mutant because this substitution is
locatedat the interfacebetween the twoAsnRS1monomers.
ARS Enzymatic Assays
In comparison with controls, AsnRS1 enzymatic activity
was reduced in proband-derived fibroblasts and lympho-
blasts. The most dramatic decrease was observed for P2
(de novo c.1600C>T [p.Arg534*]), and the mildest decrease
was observed for P24 (c.32G>C [p.Arg11Pro], 80% of the
controls). AA residue Arg11 is located in the 50 end of the
non-canonical UNE-N domain (Figure 7 and Figure S11),
which has recently been shown to elicit cell migration of
human immune cells via migration of CC chemokinettenuated inversion recovery (FLAIR) images at the age of 9months
res along with severe hypomyelination.
(p.Arg545Cyc) variant. Coronal T1-WI (4A), axial T2-WI (4B), and
-WI (4E), and sagittal T1-WI (4F) at the age of 11 years; and coronal
years. These demonstrate normal intracranial appearances across
s, which was operatively corrected at the age of 4, demonstrated on
of the chest/thoracic spine (4K).
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Figure 5. BN-PAGE and iNPC RNA-Sequencing
(A) iNPCs from P26 (c.50C>T [p.Thr17Met]) and P29 (c.203dupA [p.Met69Aspfs*4] and c.1067A>C [p.Asp356Ala]) exhibit increased
expression of most iNPC markers (sox1, sox2, nestin, snail1, pax6, DKK3, twist2, and Musashi-1) compared to fibroblast (fbb) as
measured by qPCR, shown with hierarchal clustering.
(B) Heatmap with hierarchal clustering generated using all gene counts from RNaseq distinction of control (Ctrl1 a–c, Ctrl2 a–c) and
individual-derived (P26 a–b, P29 a–c) iNPCs.
(C) Volcano plot showing log2 of fold change in NARS mutant iNPCs compared to controls and log10 (adjusted p value).
(D) BN-PAGE western blot showing reduced levels of the AsnRS1 dimer in individuals P26 and P29 and fathers compared to control, but
not for individual P10.
(E) Quantification of BN-PAGE western blot AsnRS1 dimer formation, showing significantly (***p < 0.001) reduced levels of the AsnRS1
in individuals P26 and P29 and fathers compared to control but not change for P10.
P26 ¼ homozygous c.50C>T (p.Thr17Met), P29 ¼ c.203dupA (p.Met69Aspfs*4), c.1067A>C (p.Asp356Ala), P10 ¼ c.1633C>T
(p.Arh545Cys), father of P26 ¼ heterozygous c.50C>T (p.Thr17Met), father of P29 ¼ c.1067A>C (p.Asp356Ala).receptor 3 (CCR3) in an autoimmune disease associated
with ARS genes.28Discussion
We identified de novo heterozygous and bi-allelic muta-
tions inNARS1 in 32 individuals with a neurodevelopmen-
tal phenotype. Mutations included recessivemutation hot-
spots affecting AA residues Arg534 and Arg545,
respectively, both located in the last 40 AAs of the protein.
Two homozygous variants identified at the 50 end,
c.32G>C (p.Arg11Pro) and c.50C>T (p.Thr17Met), were
associated with a severe clinical phenotype. Other muta-
tions inNARS1were spread throughout and did not cluster
in any particular region of the gene.
The clinical phenotypes associated with homozygous
variants c.32G>C (p.Arg11Pro) and c.50C>T (p.Thr17Met)
correlate with reduced protein levels and could reflect
impaired protein stability as suggested by the structural320 The American Journal of Human Genetics 107, 311–324, Augustmodeling of c.1633C>T (p.Arg545Cys) (Figure 6). Inter-
estingly, MRI imaging of individuals harboring the
c.32G>C (p.Arg11Pro) and c.50C>T (p.Thr17Met) vari-
ants showed atrophy and white matter abnormalities. In
contrast, no such changes were identified in individuals
with the p.Arg545Cys variant. The clustering of variants
and associated phenotypes at the N and C termini sug-
gests these regions are functionally important and disrupt
the protein homodimer and ATP-binding and/or catalytic
domain in NARS1. These two variants produced elevated
AsnRS1 enzyme activity, which can be attributed to their
location in the N-terminal extension domain. This
domain has additional non-translational functions,
enabling enzymatic activity of the modified protein.
When we examine protein expression, protein synthesis,
and the aminoacetylation activity, it is clear that the
non-translational functions of such ARS proteins, regu-
lated by the newly evolved appended domains such as
UNE-N, don’t seem necessary for ARS activity (Figure 7
and Figure S11).6, 2020
Figure 6. Molecular Modeling of the NARS1 p.Arg545Cys Homozygous Variant
The crystal structure is based on B.malayi AsnRS1. AsnRS1 is a homodimer; one AsnRS1 monomer is given in yellow and one in orange.
Analog of the transition state presented in the surface representation, C terminus in dark blue, Asp230 and Asp226 in cyan, Arg545 and
Arg545Cys in magenta.
(A) Interaction between AsnRS1 and tRNA with residues on the helical linker.
(B–E) Zoom in on the C terminus helical linker region, (B) and (E) show loss of molecular interaction and folding of the p.Arg545Cys
variant (*).Our functional data, including fibroblasts and iNPCs
transcriptomics, suggest that the majority of NARS1muta-
tions cause a loss of the enzymatic protein by reduced
expression and disruption of dimer formation. This re-
sults in abnormal protein synthesis and processing with
a compensatory increase in expression of other ARSs (Fig-
ures 4, 5, and 7 and Figure S11). The increased activity of
VEGFR1 and VEGFR 2 was of interest considering the re-
ported actions of other ARSs, as in GARS and EPRS via
GAIT complex, SARS1, TARS1, and mini WARS1 on
VEGF-related signaling.31 Pathways associated with
downregulated genes were typically associated with cell
cycle progression, DNA repair and replication such as
G2/M checkpoint, homology directed repair, and telo-
mere maintenance pathways; this suggests that this alter-
ation of cellular proliferation could be a result of
decreased protein synthesis (Figures S5–S10). In general,
the mutations in NARS1 resulted in loss of function in
both studied iNPC cell lines (P26 and P29), leading to a
transcriptomic signature of induced ISR, upregulation of
protein translation and processing in the ER and Golgi,
and altered ribosomal homeostasis. This is similar to the
results of other studies in cells with reduced aminoacyla-
tion activity in disease-associated mutations in other
cytosolic ARSs.5,31,32
The recurrent homozygous c.1633C>T (p.Arg545Cys)
variant in the western blot (Figure 4) and yeast model
(Figure S12) showed near normal protein levels and anThe Americincreased yeast growth suggestive of a gain-of-function
mechanism. However, protein modeling of this variant
demonstrated loss of the helix linker, and this indicates
reduced tRNA interaction and catalytic activity. This loss-
of-function effect was evidenced by the reduced aminoacy-
lation activity to 40% compared to controls (Figure 7 and
Figure S11). This effect could potentially be more harmful
for cells of the nervous system than for a unicellular organ-
ism. One of the possibilities is that the NARS1mutant mis-
charges a tRNA in the human cells that might be less
conserved in fungi. Thus, themischargingwouldbe reduced
inyeast,hence thebetter growthwithout sideeffects.Molec-
ular modeling has shown that the p.Arg545Cys variant lies
within a region that probably interacts with the sugar-phos-
phate backbone of the tRNA (at positions 68–69), close to
the active site of the enzyme.33 Replacing the bulky arginine
with a cysteine doesnot seems toperturb the enzyme’s over-
all structure (Figure 6). However, by disrupting the tRNA-
enzyme contact, this variant may alter the enzyme selec-
tivity toward tRNA, decreasing the overall affinity for
tRNA. AsnRS1 enzyme activity for individuals homozygous
for this variant (P9 and P20) showed decreased activity
(Figure 7 and Figure S11). Similarly, the de novo c.1600C>T
(p.Arg534*) variant, located adjacent to the end of the pro-
tein, has a gain-of-function effect that interferes with
normal protein function. It is likely a protein that lacks the
15 AAs containing the ATP-binding domain is produced.
This region is crucial for enzymatic function, and it escapesan Journal of Human Genetics 107, 311–324, August 6, 2020 321
Figure 7. Reduced Asparaginyl-tRNA Syn-
thetase Activity in Individuals with Homo-
zygous NARS1 Variants
c.1600C>T (p.Arg534*) (P2), c.1633C>T
(p.Arg545Cys) (P9 and P20), c.32G>C
(p.Arg11Pro) (P24), c.50C>T (p.Thr17Met)
(P26), and c.1067A>C (p.Asp356Ala)/
c.203dupA (p.M69Aspfs*4) (P29)NARS1 var-
iants in comparison to the average of three
unrelated fibroblast cell lines. (All cell lines
are fibroblast except P2, which is a lympho-
blast cell line. Control values for lympho-
blast are similar to fibroblasts.) n¼ 9, p value
FDR < 0.01.mRNA decay, as shown by semiquantitative RT-PCR from
family2 (Figure 4A).We further developed a zebrafishmodel
of this variant (FigureS13)whichelicits adominantnegative
effect on the wild-type allele, causing a dose-dependent
phenotype, specifically cyclopia and gastrulation defects at
200–500pg. Similar cyclopia defects in zebrafish were re-
ported for microcephaly gene ORC1.34
Given the essential function and constraint metrics of
NARS1, in conjunction with the clinical phenotypes of
included individuals, we propose that genotypes with
dominant heterozygous variants produce a toxic gain of
function. This is compared with the homozygous recessive
variants that probably experience a loss of function, though
this can perhaps be least partially compensated for by other
ARS genes. Taking into consideration the aminoacylation
assay and yeast model for de novomutations, and the west-
ern blot, aminoacylation assay, and modeling for homozy-
gous recessive mutations, we have confirmed the pathoge-
nicity of all NARS1 mutations mentioned. Similar effects
are seen in Aicardi-Goutie`res syndrome, which is caused
by pathogenic variants in ADAR . There are relatively
frequent alleles that are pathogenic when in trans to a
null, but are never found in individuals with the homozy-
gous state.35 For distal C terminus mutations, such as the
homozygous c.1633C>T (p.Arg545Cys) variant, the mech-
anism is likely due to abnormal protein structure and cata-
lytic activity (Figures 1C and 6 and Figures S1 and S2).
Affected individuals had both central and peripheral
nervous system involvement and a broad neurodevelop-
mental phenotype characterized by GDD, microcephaly,
ataxia, neuropathy, and seizures. This is reflective of high
NARS1 expression in the cortex, cerebellum, and brain-
stem as demonstrated inmouse brains36,37 (Figure S3). Mu-
tations have been reported for the majority of ARSs.
AsnRS2, a mitochondrial ARS protein coded by NARS2,
has recently been linked with an overlapping phenotype
consisting of multisystem mitochondrial disorder (MID).
Intellectual disability, epilepsy in childhood, hearing loss,
and myopathy have also been seen in NARS1 individ-
uals.38–41 In addition, ARS interactingmultifunctional pro-
teins 1–3 (AIMP1–3) participate together with nine cyto-
solic ARSs to constitute the so-called multi-synthetase
complex, and have also been associated with a variety of
human diseases.42 In considering their critical cellular322 The American Journal of Human Genetics 107, 311–324, Augustfunctions, we expect that all ARSs will have a disease asso-
ciation.7–9 The NARS1 data bring the number of character-
ized ARSs to 35 out of 37. On a modified Taylor’s Venn di-
agram of AA properties, NARS1 is placed in close proximity
to other AAs with similar properties (IARS1, LARS1, DARS1,
EPRS1, NARS1, RARS1, and QARS1) which also have more
severe phenotypes43 (Figure S4).
Our functional work supports the likelihood that there is
a loss-of-function mechanism in homozygotes and has
helped to further understand the role of NARS1mutations
in disease. The development of CRISPR/Cas9 heterozygous
knockin and homozygous knockout animal models is the
next important step in understanding the molecular ratio-
nale of these NARS1 variants. Considering the high num-
ber of individuals and variants identified here, the addition
of NARS1 to genetic testing panels for children and young
adults presenting with NDD, epilepsy, and/or a demyelin-
ating neuropathy may be of clinical benefit.Data and Code Availability
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